...
首页> 外文期刊>Journal of immunotherapy >Nivolumab Causing a Polymyalgia Rheumatica in a Patient With a Squamous Non-Small Cell Lung Cancer
【24h】

Nivolumab Causing a Polymyalgia Rheumatica in a Patient With a Squamous Non-Small Cell Lung Cancer

机译:Nivolumab在患有鳞状非小细胞肺癌的患者中导致多患病症

获取原文
获取原文并翻译 | 示例
           

摘要

The anti-programmed cell-death-1 antibody, nivolumab, has been recently approved for the treatment of advanced non-small cell lung cancer. Although, today, immune-related adverse effects such as dermatologic, digestive, hepatic, and endocrine toxicities are well-known with immune checkpoint inhibitors, rheumatic diseases are less well described. Herein, we report the case of a patient without a history of arthritis who developed polymyalgia rheumatica after 13 cycles of nivolumab used for the treatment of advanced non-small cell lung cancer. Laboratory evidence of inflammatory syndrome, articular echography, and clinical presentation with classical symptoms and also distal manifestations were suggestive of this chronic inflammatory disorder. Because of a relevant pain, clinicians were forced to suspend immunotherapy. Nevertheless, due to glucocorticoid therapy, the patient's symptoms have decreased progressively. Moreover, nivolumab was reintroduced 8 weeks later, whereas prednisone (10 mg) was continued, without any recurrence symptoms. To conclude, our case suggests that polymyalgia rheumatica might be a very disabling anti-programmed cell-death-1 immune-related adverse effect.
机译:抗程序性细胞死亡-1抗体nivolumab最近被批准用于治疗晚期非小细胞肺癌。尽管如今,免疫检查点抑制剂对皮肤病、消化病、肝毒性和内分泌毒性等免疫相关的不良反应已广为人知,但对风湿性疾病的描述却不那么清楚。在此,我们报告一例无关节炎病史的患者,在13个周期的nivolumab用于治疗晚期非小细胞肺癌后出现风湿性多肌痛。炎症综合征的实验室证据、关节超声、典型症状和远端表现的临床表现均提示这种慢性炎症性疾病。由于相关疼痛,临床医生被迫暂停免疫治疗。然而,由于糖皮质激素治疗,患者的症状逐渐减轻。此外,8周后再次引入nivolumab,而继续使用强的松(10 mg),没有任何复发症状。总之,我们的病例表明风湿性多肌痛可能是一种非常致残的抗程序性细胞死亡-1免疫相关不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号